Published in Biotechnol Bioeng on December 15, 2008
Comparison of two codon optimization strategies to enhance recombinant protein production in Escherichia coli. Microb Cell Fact (2011) 1.20
Inclusion bodies: a new concept. Microb Cell Fact (2010) 1.16
Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact (2009) 1.09
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
Production of recombinant proteins in the lon-deficient BL21(DE3) strain of Escherichia coli in the absence of the DnaK chaperone. Appl Environ Microbiol (2009) 0.88
Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol (2009) 0.84
Inclusion bodies as potential vehicles for recombinant protein delivery into epithelial cells. Microb Cell Fact (2012) 0.83
Expanding the recombinant protein quality in Lactococcus lactis. Microb Cell Fact (2014) 0.81
Synonymous rare arginine codons and tRNA abundance affect protein production and quality of TEV protease variant. PLoS One (2014) 0.77
Disulfide bond formation and activation of Escherichia coli β-galactosidase under oxidizing conditions. Appl Environ Microbiol (2012) 0.77
Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. Microb Cell Fact (2011) 0.77
Cross-system excision of chaperone-mediated proteolysis in chaperone-assisted recombinant protein production. Bioeng Bugs (2009) 0.75
Protein quality in bacterial inclusion bodies. Trends Biotechnol (2006) 2.02
Amyloid-like properties of bacterial inclusion bodies. J Mol Biol (2005) 1.90
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact (2005) 1.79
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact (2009) 1.59
The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng (2007) 1.34
Recombinant protein solubility - does more mean better? Nat Biotechnol (2007) 1.21
Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol (2006) 1.20
Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol (2007) 1.18
Role of molecular chaperones in inclusion body formation. FEBS Lett (2003) 1.16
Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. J Bacteriol (2005) 1.12
Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact (2009) 1.09
Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact (2010) 1.09
Biomedical applications of distally controlled magnetic nanoparticles. Trends Biotechnol (2009) 1.08
Bacterial inclusion bodies: making gold from waste. Trends Biotechnol (2011) 1.07
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnol Adv (2012) 1.05
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J (2011) 1.01
Folding of a misfolding-prone beta-galactosidase in absence of DnaK. Biotechnol Bioeng (2005) 1.01
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology (2010) 1.00
Nanostructured bacterial materials for innovative medicines. Trends Microbiol (2010) 0.95
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microb Cell Fact (2006) 0.95
The Functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol (2008) 0.94
Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol (2008) 0.91
Lactic Acid Bacteria: a promising alternative for recombinant protein production. Microb Cell Fact (2012) 0.91
The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials (2010) 0.90
Systems metabolic engineering, industrial biotechnology and microbial cell factories. Microb Cell Fact (2012) 0.90
Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol (2011) 0.89
Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater (2012) 0.89
Modular protein engineering for non-viral gene therapy. Trends Biotechnol (2004) 0.88
Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. J Biotechnol (2005) 0.87
Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) (2010) 0.87
Insertional protein engineering for analytical molecular sensing. Microb Cell Fact (2006) 0.87
Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies. Biochem Biophys Res Commun (2007) 0.87
Influence of growth temperature on the production of antibody Fab fragments in different microbes: a host comparative analysis. Biotechnol Prog (2010) 0.86
Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-forming Escherichia coli cells. FEMS Microbiol Lett (2007) 0.86
Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnol Adv (2009) 0.86
Modular protein engineering in emerging cancer therapies. Curr Pharm Des (2009) 0.86
Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. Microb Cell Fact (2012) 0.86
Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. Biochem Biophys Res Commun (2004) 0.85
Production of functional inclusion bodies in endotoxin-free Escherichia coli. Appl Microbiol Biotechnol (2014) 0.85
Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol (2009) 0.84
Post-production protein stability: trouble beyond the cell factory. Microb Cell Fact (2011) 0.84
Lon and ClpP proteases participate in the physiological disintegration of bacterial inclusion bodies. J Biotechnol (2005) 0.83
Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact (2011) 0.83
Fast electrochemical detection of anti-HIV antibodies: coupling allosteric enzymes and disk microelectrode arrays. Anal Chim Acta (2009) 0.83
In situ protein folding and activation in bacterial inclusion bodies. Biotechnol Bioeng (2008) 0.83
Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials (2010) 0.83
Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. Nanomedicine (Lond) (2015) 0.82
Recombinant protein quality evaluation: proposal for a minimal information standard. Stand Genomic Sci (2011) 0.82
Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today (2008) 0.81
General introduction: recombinant protein production and purification of insoluble proteins. Methods Mol Biol (2015) 0.81
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine (2012) 0.81
Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. Appl Microbiol Biotechnol (2015) 0.81
Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochem Biophys Res Commun (2003) 0.81
Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors. Biochim Biophys Acta (2002) 0.81
DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. Appl Microbiol Biotechnol (2009) 0.80
Interleukin-10 overexpression does not synergize with the neuroprotective action of RGD-containing vectors after postnatal brain excitotoxicity but modulates the main inflammatory cell responses. J Neurosci Res (2011) 0.80
Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomater (2012) 0.80
The impact of dnaKJ overexpression on recombinant protein solubility results from antagonistic effects on the control of protein quality. Biotechnol Lett (2004) 0.80
High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. Mol Immunol (2006) 0.79
Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond. Nanomedicine (Lond) (2013) 0.79
Cellular uptake and intracellular fate of protein releasing bacterial amyloids in mammalian cells. Soft Matter (2016) 0.79
A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs. Nanomedicine (Lond) (2013) 0.79
Analytical approaches for assessing aggregation of protein biopharmaceuticals. Curr Pharm Biotechnol (2011) 0.79
Control of Escherichia coli growth rate through cell density. Microbiol Res (2002) 0.79
Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering. Nanomedicine (Lond) (2011) 0.79
Nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions. Nanomedicine (Lond) (2011) 0.79
Overexpression of the nuclear factor kappaB inhibitor A20 is neurotoxic after an excitotoxic injury to the immature rat brain. Neurol Res (2012) 0.78
In vivo architectonic stability of fully de novo designed protein-only nanoparticles. ACS Nano (2014) 0.78
Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay. J Biomol Screen (2010) 0.78
Bacterial inclusion bodies: an emerging platform for drug delivery and cell therapy. Nanomedicine (Lond) (2012) 0.78
RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine (2012) 0.78
Topographically targeted osteogenesis of mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces. Nanomedicine (Lond) (2013) 0.78
Antiretroviral therapy-induced functional modification of IgG4 and IgM responses in HIV-1-infected individuals screened by an allosteric biosensor. J Biomol Screen (2008) 0.77
Discriminating foot-and-mouth disease virus-infected and vaccinated animals by use of beta-galactosidase allosteric biosensors. Clin Vaccine Immunol (2009) 0.77
Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials (2012) 0.77
Disulfide bond formation and activation of Escherichia coli β-galactosidase under oxidizing conditions. Appl Environ Microbiol (2012) 0.77
Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. Microb Cell Fact (2011) 0.77
Two-dimensional microscale engineering of protein-based nanoparticles for cell guidance. ACS Nano (2013) 0.77
Engineering of Escherichia coli beta-galactosidase for solvent display of a functional scFv antibody fragment. FEBS Lett (2003) 0.77